Mitochondrial proteomics of colorectal cancer cells study of the effects of butyrate and subcellular expression of mortalin

MITOCHONDRIAL PROTEOMICS OF COLORECTAL CANCER CELLS: STUDY OF THE EFFECTS OF BUTYRATE & SUBCELLULAR EXPRESSION OF MORTALIN KUAH LI FANG (B.Sc (Hons.), NUS) A THESIS SUBMITTED FOR THE DEGREE OF MASTER OF SCIENCE DEPARTMENT OF BIOCHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2008 ACKNOWLEDGEMENTS This project would not have been possible without the patient guidance and constant encouragement of my supervisors, Associate Professor Maxey Chung and Dr Sandra Tan I am truly grateful to Prof Chung, my project supervisor and Life Sciences coordinator, for giving me the chance and courage to pursue my Masters degree in his lab My deepest thanks also go to Sandra, who has been my mentor and dear sister in Christ, for her invaluable advice and inspiring example of perseverance and faith, in research work and life I would also like to thank Associate Professor Hooi Shing Chuan who has kindly provided the cell lines used in this project and whose lab, in Department of Physiology, first started this study of colon cancer cells and butyrate treatment I have been truly blessed for the many opportunities of growth and training in our lab team—the “MaxProteomics team” For this, I am deeply grateful to Dr Lin Qinsong, Gek San, Cynthia, Teck Kwang, and Jason—the dedicated researchers whose expertise and kind support have contributed greatly to my project and nurtured me in research life I would also like to acknowledge my fellow lab-mates and friends in MaxProteomics: THT, for his faithful teaching of techniques and help; Aida, for the amazing brainstorming and sharing sessions that never failed to motivate me; Jiayi, for the selfless sharing of knowledge and experiences; Xuxiao, for showing me how to smile through failures and disappointments; as well as the rest of my team-mates—Jack, Vincent, Hong Qing, Hendrick and Wenchun—who have added much fun and joy to the whole learning journey My heartfelt appreciation also goes to our “computer doctors”, Tiefei and Eric, for the much-needed help and counsel in IT and bioinformatics I am also thankful for the well-equipped facilities in Protein Proteomics Centre, faithfully maintained by its friendly staff I would also like to give thanks to my family, especially my parents, for their unfailing support and faith in me through the years and through the writing of this thesis Their unquestioning love, understanding and sacrifices have given me much strength and meaning in work and life Finally, I give all credit for the completion of this thesis and its potential future contribution to cancer treatment, to God, who is truly my Ever-present Help in times of need and the Sole Provider of my competence and work I would like to thank Him for the many blessings in my life, including the warm acceptance and prayer support from my spiritual family in Saint James Church His grace is indeed sufficient and His wisdom, infinite, as demonstrated by the gift of Science and research i CONTENTS ACKNOWLEDGEMENTS ……………………………………………………… i TABLE OF CONTENTS ….……………………………………………………… ii SUMMARY ……………… ……………………………………………………… viii LIST OF TABLES ………………………………………………………………… x LIST OF FIGURES ………………………………………………………………… xi ABBREVIATIONS AND SYMBOLS USED …………………………… xiii INTRODUCTION 1.1 COLORECTAL CANCER (CRC) 1.1.1 Epidemiology 1.1.2 Limits of current CRC diagnosis methods 1.1.3 Limits of current CRC treatment 1.1.4 Grounds for modern cancer research 1.1.5 Early cellular events in CRC carcinogenesis 1.1.6 Genetic models of CRC carcinogenesis 1.1.6.1 Chromosomal instability (CIN) pathway 1.1.6.2 Microsatellite instability (MIN) pathway 1.1.7 Epigenetic pathway of CRC carcinogenesis via methylation 10 1.1.8 Risk factors of CRC 11 1.1.8.1 Genetic risk factors 11 1.1.8.2 Environmental risk factors 12 1.1.8.3 Chemopreventive role of dietary fibre 12 1.1.8.4 Dietary fibre protects against CRC via SCFAs production 13 1.2 BUTYRATE AND CRC 14 1.2.1 Butyrate as potential chemotherapeutic agent against CRC 14 1.2.2 Role of SCFA butyrate in colonic health and cancer 14 1.2.2.1 Essential nutrient of the colon 14 ii 1.2.2.2 Modulator of colonic cell growth and maturation 15 1.2.2.3 Modulator of the gut inflammation and immunity 16 1.2.2.4 Anti-cancer effects of butyrate 17 1.2.3 Molecular mechanisms for butyrate anti-neoplastc effects 17 1.2.3.1 Histone acetylation and deacetylation in gene expression 17 1.2.3.2 Role of HDAC in carcinogenesis 19 1.2.3.3 Butyrate inhibition of HDAC 19 1.2.3.4 Effects of butyrate mediated through histone hyperacetylation 23 1.2.3.5 Effects of butyrate through non-histone substrates of HDACs 24 1.3 BUTYRATE EFFECTS THROUGH THE MITOCHONDRIA IN CANCER 26 1.3.1 The mitochondrial organelle as a key player in cell life and death 26 1.3.2 Mitochondria in cancer 26 1.3.2.1 Energy metabolism in cancer cells 26 1.3.2.2 Apoptosis resistance in cancer cells 27 1.3.2.3 Other characteristics of cancer cell mitochondria 29 1.3.3 Butyrate effects through the cancer cell mitochondria 32 1.3.3.1 Alteration of the metabolic profile of cancer cell 32 1.3.3.2 Potentiation of intrinsic apoptosis via MOMP 33 1.4 THE PROTEOMICS APPROACH 1.4.1 Why proteomics? 34 34 1.4.1.1 The dynamic proteome 35 1.4.1.2 Proteomics as a discovery tool 36 1.4.2 Technologies in proteomics 36 1.4.2.1 Two-dimensional gel electrophoresis / mass spectrometry approach (2-DE/MS) 37 1.4.2.2 Two-dimensional difference gel electrophoresis (2D-DIGE) 38 1.4.3 Subproteomics—when less is more 1.4.3.1 Mitochondrial proteomics 38 39 iii 1.4.3.2 Study of the effects of butyrate on the mitochondrial proteome 1.5 PROJECT AIMS MATERIALS AND METHODS 40 41 42 2.1 CELL LINES AND CELL CULTURE 42 2.2 SAMPLE PREPARATION 42 2.2.1 Butyrate treatment and harvesting of cells 42 2.2.2 Whole cell lysates 43 2.2.3 Subcellular fractions 43 2.2.3.1 Mitochondrial enrichment 44 2.2.3.2 Cytosol enrichment 44 2.2.3.3 Nuclear enrichment 44 2.3 PROTEIN ASSAY 45 2.4 2-D DIGE 45 2.4.1 CyDye labeling 45 2.4.2 IEF 46 2.4.3 2-DE 46 2.4.4 Fluorescence scanning and protein visualisation 47 2.4.5 DeCyder image analysis 47 2.4.6 Vorum Silver Staining 48 2.5 MASS SPECTROMETRY (MS) 49 2.5.1 Enzymatic digestion of protein spots 49 2.5.2 MS and database searching 50 2.6 SDS-PAGE / WESTERN BLOT 51 2.6.1 1-D SDS-PAGE 51 2.6.2 1-D western immunodetection 52 2.6.3 2-D western immunodetection 53 2.6.4 Visualisation of immunoreactive proteins 54 iv 2.6.5 MS/MS confirmation of mortalin isoforms 2.7 BIOINFORMATIC PREDICTIONS 54 56 2.7.1 Phosphorylation sites prediction via NetPhos 56 2.7.2 Phosphorylation sites prediction via Scansite 56 57 RESULTS 3.1 ENRICHMENT OF HCT 116 MITOCHONDRIAL PROTEOME 57 3.1.1 Enrichment of mitochondrial marker upon subcellular fractionation 57 3.1.2 2-DE profile of HCT 116 mitochondrial proteome 59 3.2 MITOCHONDRIAL PROTEOMICS OF BUTYRATE-TREATED HCT 116 CELLS 67 3.2.1 Batch-to-batch reproducibility among mitochondrial fractions 67 3.2.2 2-D DIGE analysis of HCT 116 mitochondrial proteome changes upon butyrate treatment 68 Proteome alterations in the HCT 116 mitochondria upon butyrate treatment 70 3.3 BUTYRATE REGULATION OF MORTALIN EXPRESSION IN CRC CELLS 77 3.2.3 3.3.1 Characterisation of mortalin isoforms in HCT 116 whole cell and mitochondrial fractions 78 3.3.1.1 Mortalin isoforms detected at HCT 116 whole cell level 78 3.3.1.2 Mortalin isoforms detected in HCT 116 mitochondrial fraction 80 3.3.2 Butyrate-induced changes in mortalin expression in HCT 116 83 3.3.2.1 Butyrate regulation of mortalin isoforms at whole cell level 83 3.3.2.2 Butyrate regulation of HCT 116 mitochondrial mortalin isoforms 85 3.3.2.3 Detection of serine and tyrosine phosphorylation in butyrateregulated mitochondrial mortalin isoforms 85 3.3.2.4 Prediction of phosphorylation sites in mortalin 88 3.3.2.5 Butyrate effects on mortalin level in HCT 116 subcellular fractions 91 3.3.2.6 Regulation of mortalin isoforms in HCT 116 nuclear fraction 93 v 3.3.2.7 Regulation of mortalin isoforms in HCT 116 cytosolic fraction 3.3.3 93 Butyrate-induced changes in mortalin expression in HT-29 95 3.3.3.1 Butyrate regulation on mortalin level in HT-29 subcellular fractions 95 3.3.3.2 Butyrate-induced changes at HT-29 whole cell level 98 3.3.3.3 Butyrate-induced changes in HT-29 mitochondrial fraction 98 3.3.3.4 Butyrate-induced changes in HT-29 nuclear fraction 99 3.3.3.5 Butyrate-induced changes in HT-29 cytosolic fraction 99 3.3.4 Differential regulation of mortalin isoforms in HCT 116 and HT-29 upon butyrate treatment DISCUSSION 4.1 HCT 116 MITOCHONDRIAL PROTEOME 101 103 103 4.1.1 Enrichment of mitochondrial proteome 103 4.1.2 2-DE/MS/MS survey of HCT 116 mitochondrial proteome 105 4.2 MITOCHONDRIAL PROTEOMICS OF BUTYRATE-TREATED HCT 116 4.2.1 4.2.2 106 2-D DIGE analysis of HCT 116 mitochondrial proteome changes upon butyrate treatment 106 Butyrate-regulated mitochondrial proteins in HCT 116 108 4.2.2.1 Oxidative metabolic enzymes 108 4.2.2.2 Redox enzymes 109 4.2.2.3 Respiratory chain complex subunits 111 4.2.2.4 Players of apoptosis and cell death 111 4.2.2.5 Members of the mitochondrial translation system 112 4.2.2.6 Regulators of mitochondrial protein import and folding 112 4.3 BUTYRATE REGULATION OF MORTALIN EXPRESSION IN CRC CELLS 4.3.1 Characterisation of mortalin isoforms with differential subcellular expression in HCT 116 4.3.1.1 Mortalin was present most abundantly in HCT 116 mitochondrial fractions 114 115 116 vi 4.3.1.2 Different mortalin isoforms were found in different subcellular fractions in HCT 116 cells 117 4.3.1.3 pSer and pTyr residues were detected mainly in mortalin isoforms a, b, and c 120 4.3.1.4 Mortalin was found more abundantly in HCT 116 nuclear fraction compared to the cytosolic fraction 121 4.3.1.5 Two mortalin isoforms, d and e, were preferentially present in HCT 116 mitochondrial and nuclear fractions 122 4.3.2 4.3.3 Butyrate effects on the mortalin level in HCT 116 subcellular fractions 124 Differential regulation of HCT 116 mortalin isoforms by butyrate 124 4.3.3.1 HCT 116 mortalin isoforms were regulated by butyrate only at specific subcellular levels 125 4.3.3.2 Re-distribution of mortalin isoforms d and e was detectable upon prolonged butyrate treatment 126 4.3.3.3 Mortalin isoform d was specifically associated with butyrateinduced cell death 127 4.3.3.4 Butyrate preferentially down-regulated mortalin isoform d in HCT 116 mitochondrial fraction 128 4.3.4 Comparison of butyrate regulation of mortalin HCT 116 and HT-29 131 4.3.4.1 Extensive down-regulation of subcellular mortalin isoforms was associated with resistance to butyrate-induced apoptosis 131 4.3.4.2 HT-29 expressed only trace levels of mortalin isoforms d and e 133 CONCLUSION AND FUTURE DIRECTIONS 135 BIBLIOGRAPHY 138 LIST OF CONFERENCES FOR POSTER PRESENTATIONS 156 vii SUMMARY Colorectal cancer (CRC) is currently the most prevalent malignancy in developed countries, accounting for over half a million deaths annually The high mortality of CRC is largely due to late diagnosis and the lack of effective adjunctive treatment and preventive chemotherapeutics Butyrate, a short-chain fatty acid produced during colonic bacteria fermentation of dietary fibre, has been shown to protect against CRC by inducing growth arrest, differentiation and apoptosis of cancer cells In addition to regulating gene expression through its histone deacetylase inhibitor (HDACi) activities, butyrate has also been shown to directly affect the energy metabolism and apoptotic resistance in cancer cells The mitochondrion has been shown to be a crucial player in the anti-neoplastic effects of butyrate, but the precise molecular pathways remain unclear To determine the direct biochemical effects of butyrate on the mitochondria of colon cancer cells, we used a sub-proteomics approach to study the differential expression of mitochondrial proteins in HCT-116 human CRC cells treated with 5mM butyrate for 24 hours To accomplish this, mitochondrial fractions of the untreated and butyratetreated samples were compared by 2-dimensional difference gel electrophoresis (2-D DIGE) Subsequent tandem mass spectrometry (MS/MS) analysis identified 28 butyrate-regulated proteins, out of which 18 were found to have mitochondrial functions based on published literature These proteins include metabolic and redox enzymes; regulators of protein import, folding and assembly in the organelle; components of the mitochondrial translational apparatus; subunits of various respiratory complexes; as well as translocated proteins involved in apoptosis and cell death This supports the association of the protective effects of butyrate with its biochemical effects on the mitochondria of cancer cells viii In particular, one of the mitochondrial proteins found to be significantly downregulated by butyrate, was the mitochondrial heat shock protein 70 (mthsp70), which is also known as mortalin This protein was recently reported to be overexpressed in colorectal adenocarcinomas and positively correlated with poor prognosis in CRC The down-regulation of mortalin by the anti-cancer agent, butyrate, could be an important mechanism of chemoprotection by the latter Using immunoassays, we characterised mortalin isoforms (a, b, c, d, and e) and their specific regulation by butyrate, in the whole cell lysate and various subcellular fractions of HCT 116 cells Most interestingly, two mortalin isoforms, d and e, were found to be significantly suppressed by butyrate in both the mitochondrial and nuclear fractions, but up-regulated in the whole cell lysate upon prolonged butyrate treatment In addition, isoform d was found to be present specifically in the floating, apoptotic cell population of 72-hr butyrate-treated HCT 116 cells, further indicating the association between this mortalin isoform with butyrate-induced apoptosis Furthermore, we also showed that these two mortalin isoforms were expressed in much lower levels in the subcellular fractions of HT-29 cells, a relatively more butyrate-resistant CRC cell line This resulted in a different expression profile of mortalin upon butyrate perturbation Hence, we suggest that the various mortalin isoforms may serve different functions in determining the susceptibility of CRC cells to butyrate treatment (495 words) ix Bibliography Kamangar, F., Dores, G.M., and Anderson, W.F (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J Clin Oncol 24(14), 2137-50 Kanai, M., Ma, Z., Izumi, H., Kim, S.H., Mattison, C.P., Winey, M., and Fukasawa, K (2007) Physical and functional interaction between mortalin and Mps1 kinase, Genes Cells 12(6), 797-810 Kaul, S.C., Wadhwa, R., Komatsu, Y., Sugimoto, Y., and Mitsui, Y (1993) On the cytosolic and perinuclear mortalin: an insight by heat shock, Biochem Biophys Res Commun 193(1), 348-55 Kaul, S.C., Duncan, E.L., Englezou, A., Takano, S., Reddel, R.R., Mitsui, Y., and Wadhwa, R (1998) Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein, Oncogene 17(7), 907-11 Kaul, S.C., Aida, S., Yaguchi, T., Kaur, K., and Wadhwa, R (2005) Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides, J Biol Chem 280(47), 39373-9 Kaul, S.C., Deocaris, C.C., and Wadhwa, R (2007) Three faces of mortalin: a housekeeper, guardian and killer, Exp Gerontol 42(4), 263-74 Kawai, A., Nishikawa, S., Hirata, A., and Endo, T (2001) Loss of the mitochondrial Hsp70 functions causes aggregation of mitochondria in yeast cells, J Cell Sci 114(Pt 19), 3565-74 Kersey, P.J., Duarte, J., Williams, A , Karavidopoulou, Y., Birney, E., Apweiler, R (2004) The International Protein Index: An integrated database for proteomics experiments Proteomics 4(7), 1985-1988 Kim, K.B., Lee, J.W., Lee, C.S., Kim, B.W., Choo, H.J., Jung, S.Y., Chi, S.G., Yoon, Y.S., Yoon, G., and Ko, Y.G (2006a) Oxidation-reduction respiratory chains and ATP synthase complex are localized in detergent-resistant lipid rafts, Proteomics 6(8), 2444-53 Kim, S.C., Sprung, R., Chen, Y., Xu, Y., Ball, H., Pei, J., Cheng, T., Kho, Y., Xiao, H., Xiao, L., Grishin, N.V., White, M., Yang, X.J., and Zhao, Y (2006b) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey, Mol Cell 23(4), 607-18 Kobayashi, H., Tan, E.M., and Fleming, S.E (2004) Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells, Int J Cancer 109(2), 207-13 Kohli, M., Yu, J., Seaman, C., Bardelli, A., Kinzler, K.W., Vogelstein, B.,Lengauer, C., and Zhang, Lin (2004) SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells, PNAS 101 (48), 16897–16902 145 Bibliography Kroemer, G (2006) Mitochondria in cancer, Oncogene 25(34), 4630-2 Kucerova, D., Stokrova, J., Korb, J., Sloncova, E., Tuhackova, Z., and Sovova, V (2002) Response of HT29 cells to butyrate depends on time of exposure and glucose deprivation, Int J Mol Med 10(6), 779-84 Langer, T., Kaser, M., Klanner, C., and Leonhard, K (2001) AAA proteases of mitochondria: quality control of membrane proteins and regulatory functions during mitochondrial biogenesis Biochem Soc Trans 29(Pt 4), 431-6 Lee, H.H., Chien, C.L., Liao, H.K., Chen, Y.J., and Chang, Z.F (2004) Nuclear efflux of heterogeneous nuclear ribonucleoprotein C1/C2 in apoptotic cells: a novel nuclear export dependent on Rho-associated kinase activation, J Cell Sci 117(Pt 23), 5579-89 Leder, A., Orkin, S., and Leder, P (1975) Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis, Science 190(4217), 893-4 Leong, A., Tang, C.L., Sim, R., Lim, R., Wynne, C., Lee, K.S., Koo, W.H., and Kang, A.K (2004) Clinical Practice Guidelines; Colorectal Cancer, MOH Clinical Practive Guidelines 2/2004, 8-83 Levy, P., Robin, H., Bertrand, F., Kornprobst, M., and Capeau, J (2003) Butyrate-treated colonic Caco-2 cells exhibit defective integrin-mediated signaling together with increased apoptosis and differentiation, J Cell Physiol 197, 336-347 Liang, C.R., Leow, C.K., Neo, J.C., Tan, G.S., Lo, S.L., Lim, J.W., Seow, T.K., Lai, P.B., and Chung, M.C (2005) Proteome analysis of human hepatocellular carcinoma tissues by twodimensional difference gel electrophoresis and mass spectrometry, Proteomics 5(8), 2258-71 Lim, Y.P., Diong, L.S., Qi, R., Druker, B.J., and Epstein, R.J (2003) Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells, Mol Cancer Ther 2(12), 1369-77 Lim, Y.P., Wong, C.Y., Ooi, L.L., Druker, B.J., and Epstein, R.J (2004) Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs, Clin Cancer Res 10(12 Pt 1), 39807 Lopez, M.F., and Melov, S (2001) Applied proteomics; Mitochondrial proteins and effect on function, Circ Res 90, 380-389 Mann, M., and Jensen, O.N (2003) Proteomic analysis of post-translational modifications, Nat Biotechnol 21(3), 255-61 146 Bibliography Mariadason, J.M., Velcich, A., Wilson, A.J., Augenlicht, L.H., and Gibson, P.R (2001) Resistance to Butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation, Gastroenterology 120, 889-899 Marks, P.A., Richon, V.M., and Rifkind, R.A (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92(15), 12106 Marchenko, N.D., Zaika, A., and Moll, U.M.(2000) Death signal-induced localisation of p53 protein to mitochondria.—A potential role in apoptotic signaling J Biol Chem 275(21), 16202-12 Mathupala, S.P., Ko, Y.H., and Pedersen, P.L (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria, Oncogene 25(34), 4777-86 Matsuoka, S., Ballif, B.A., Smogorzewska, A., McDonald, E.R 3rd, Hurov, K.E., Luo, J., Bakalarski, C.E., Zhao, Z., Solimini, N., Lerenthal, Y., Shiloh, Y., Gygi, S.P., and Elledge, S.J (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage, Science 316(5828), 1160-6 Mazzanti, R., Solazzo, M., Fantappie, O., Elfering, S., Pantaleo, P., Bechi, P., Cianchi, F., Ettl, A., and Giulivi, C (2006) Differential expression proteomics of human colon cancer, Am J Physiol Gastrointest Liver Physiol 290(6), G1329-38 McDonald, T.G., and Van Eyk, J.E (2003) Mitochondrial proteomics; Undercover in the lipid bilayer, Basic Res Cardiol 98, 219-227 McIntyre, A., Gibson, P.R., and Young, G.P (1993) Butyrate production from dietary fibre and protection against large bowel cancer in a rat model, Gut 34, 386-391 Meisenholder, G (2000) Live and Let Die, Mitochondrial research is coming back – here are some of the tools you’ll need to get in on the action, The Scientist 14(1):http://www.thescientist.com/yr2000/jan/profile1_000110.html Minucci, S., and Pelicci, P.G (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat Rev Cancer 6(1), 38-51 Miyamoto, K., and Ushijima, T (2005) Diagnostic and therapeutic applications of epigenetics Jpn J Clin Oncol 35(6), 293-301 Mizukoshi, E., Suzuki, M., Loupatov, A., Uruno, T., Hayashi, H., Misono, T., Kaul, S.C., Wadhwa, R., and Imamura, T (1999) Fibroblast growth factor-1 interacts with the glucoseregulated protein GRP75/mortalin, Biochem J 343(Pt 2), 461-6 147 Bibliography Mizukoshi, E., Suzuki, M., Misono, T., Loupatov, A., Munekata, E., Kaul, S.C., Wadhwa, R., and Imamura, T (2001) Cell-cycle dependent tyrosine phosphorylation on mortalin regulates its interaction with fibroblast growth factor-1, Biochem Biophys Res Commun 280(4), 12039 Mizzen, L.A., Kabiling, A.N., and Welch, W.J (1991) The two mammalian mitochondrial stress proteins, grp 75 and hsp 58, transiently interact with newly synthesized mitochondrial proteins, Cell Regul 2(2), 165-79 Modrek, B., and Lee, C (2002) A genomic view of alternative splicing, Nat Genet 30(1), 13-9 Mohr, B., and Illmer, T (2005) Structural chromosomal aberrations in the colon cancer cell line HCT 116—results of investigations based on spectral karyotyping, Cytogenet Genome Res 108(4), 359-61 Moreno-Sanchez, R., Rodriguez-Enriquez, S., Marin-Hernandez, A., and Saavedra, E (2007) Energy metabolism in tumor cells, FEBS J 274(6), 1393-418 Mortz, E., Krogh, T.N., Vorum, H., and Gorg, A (2001) Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionizationtime of flight analysis, Proteomics 1(11), 1359-63 Muntener, K., Zwicky, R., Csucs, G., and Baici, A (2003) The alternative use of exons and in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells, Histochem Cell Biol 119(2), 93-101 Muntener, K., Zwicky, R., Csucs, G., Rohrer, J., and Baici, A (2004) Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase provokes cell death, J Biol Chem 279(39), 41012-7 Murata, T., Goshima, F., Daikoku, T., Inagaki-Ohara, K., Takakuwa, H., Kato, K., and Nishiyama, Y (2000) Mitochondrial distribution and function in herpes simplex virusinfected cells, J Gen Virol 81(Pt 2), 401-6 Myzak, M.C., and Dashwood, R.H (2006) Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane, Curr Drug Targets 7(4), 443-52 Natoni, F., Diolordi, L., Santoni, C., Gilardini Montani, M.S (2005) Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways, Biochim Biophys Acta 1745(3), 318-29 Neo, J.C., Rose, P., Ong, C.N., and Chung, M.C (2005) beta-Phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes, Proteomics 148 Bibliography 5(4), 1075-82 Obenauer, J.C., Cantley, L.C., and Yaffe, M.B (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs, Nucleic Acids Res 31(13), 3635-41 Obrador, E., Carretero, J., Esteve, J.M., Pellicer, J.A., Pascual, A., Petschen, I., and Estrela, J.M (2001) Glutamine potentiates TNF-alpha-induced tumor cytotoxicity, Free Radic Biol Med 31(5), 642-50 Orsini, F., Migliaccio, E., Moroni, M., Contursi, C., Raker, V.A., Piccini, D., Martin-Padura, I., Pelliccia, G., Trinei, M., Bono, M., Puri, C., Tacchetti, C., Ferrini, M., Mannucci, R., Nicoletti, I., Lanfrancone, L., Giorgio, M., and Pelicci, P.G (2004) The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential J Biol Chem 279(24), 25689-95 Osborn, N.K., and Ahlqiust, D.A (2005) Stool Screening for Colorectal Cancer: Molecular Approaches, Gastroenterology 128, 192-206 Oshiro, M.M., Watts, G.S., Wozniak, R.J., Junk, D.J., Munoz-Rodriguez, J.L., Domann, F.E., and Futscher, B.W (2003) Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression, Oncogene 22(23), 3624-34 Osorio, C., Sullivan, P.M., He, D.N., Mace, B.E., Ervin, J.F., Strittmatter, W.J., and Alzate, O (2006) Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice, Neurobiol Aging [Epub ahead of print] Ostrowski, J., Wyrwicz, L., Rychlewski, L., and Bomsztyk, K (2002) Heterogeneous nuclear ribonucleoprotein K protein associates with multiple mitochondrial transcripts within the organelle, J Biol Chem 277(8), 6303-10 Ostrowski, J., Klimek-Tomczak, K., Wyrwicz, L.S., Mikula, M., Schullery, D.S., Bomsztyk, K (2004) Heterogeneous nuclear ribonucleoprotein K enhances insulin-induced expression of mitochondrial UCP2 protein, J Biol Chem 279(52), 54599-609 Ozoren, N., and El-Deiry, W (2002) Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis, Exp Cell Res 281(2), 175-81 Pandha, H.S., and Sikora, K (1997) Neoplasia In Mechanisms of Disease; An introduction to clinical science, S Tomlinson, A.M Heagerty, and A.P Weetman, ed (United Kingdom: Cambridge University Press), p 322-362 Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P (2005) Global cancer statistics, 2002, CA Cancer J Clin 55(2), 74-108 149 Bibliography Patton, W.F (2002) Detection technologies in proteome analysis, J Chromatogr B 771, 331 Potten, C.S., Wilson, J.W., and Booth, C (1997) Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium, Stem Cells 15(2), 82-93 Prokisch, H., Andreoli, C., Ahting, U., Heiss, K., Ruepp, A., Scharfe, C., and Meitinger, T (2006) MitoP2: the mitochondrial proteome database—now including mouse data, Nucleic Acids Res 34(Database issue), D705-11 Rabilloud, T (2002) Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains, Proteomics 2, – 10 Rabilloud, T., Strub, J.M., Carte, N., et al (2002) Comparative proteomics as a new tool for exploring human mitochondrial tRNA disorders, Biochemistry 41, 144-150 Radi, R., Turrens, J.F., Chang, L.Y., Bush, K.M., Crapo, J.D., Freeman, B.A (1991) Detection of catalase in rat heart mitochondria, J Biol Chem 266(32), 22028-34 Radtke, F., and Clevers, H (2005) Self-renewal and cancer of the gut: two sides of a coin, Science 307(5717), 1904-9 Ragione, F.D., Criniti, V., Pietra, V.D., Borriello, A., Oliva, A., Indaco, S., Yamamoto, T., and Zappia, V (2001) Genes modulated by histone acetylation as new effectors of butyrate activity, FEBS Lett 499, 199-204 Ragnhammar, P., Hafstrom, L., Nygren, P., and Glimelius, B (2001) A systematic overview of chemotherapy effects in colorectal cancer, Acta Oncol 40, 282-308 Ran, Q., Wadhwa, R., Kawai, R., Kaul, S.C., Sifers, R.N., Bick, R.J., Smith, J.R., PereiraSmith, O.M (2000) Extramitochondrial localisation of mortalin/mthsp70 /PBP74/GRP75, Biochem Biophys Res Commun 275(1), 174-9 Rang, H.P., Dale, M.M., Ritter, J.M., and Moore, P.K (2003) Cancer Chemotherapy In Pharmacology, 5th Ed., (UK: Churchill Livingstone) p 693-710 Renehan, A.G., O'Dwyer, S.T., Haboubi, N.J., and Potten, C.S (2002) Early cellular events in colorectal carcinogenesis, Colorectal Dis 4(2), 76-89 Renehan, A.G., and Shalet, S.M (2005) Diabetes, insulin therapy, and colorectal cancer, BMJ 330(7491), 551-2 Ricci, J.E., Pinedo, C.M., Fitzgerald, P., Maitre, B.B., Perkins, G.A., Yadava, N., Scheffler, I.E., Ellisman, M.H., and Green, D.R (2004) Disruption of Mitochondrial Function during 150 Bibliography Apoptosis Is Mediated by Caspase Cleavage of the p75 Subunit of Complex I of the Electron Transport Chain, Cell 117, 773-786 Riggs, M.G., Whittaker, R.G., Neumann, J.R., and Ingram, V.M (1977) n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells Nature 268(5619), 462-4 Ross, J.S., Schenkein, D.P., Pietrusko, R., Rolfe, M., Linette, G.P., Stec, J., Stagliano, N.E., Ginsburg, G.S., Symmans, W.F., Pusztai, L., and Hortobagyi, G N (2004) Targeted Therapies for Cancer 2004, Am J Clin Pathol 122, 598-609 Rougier, P., and Mitry, E (2003) Epidemiology, treatment and chemoprevention in colorectal cancer, Ann Oncol 14, (Supplement 2): ii3–ii5 Salvi, M., Battaglia, V., Brunati, A.M., La Rocca, N., Tibaldi, E., Pietrangeli, P., Marcocci, L., Mondovi, B., Rossi, C.A., and Toninello, A (2007) Catalase takes part in rat liver mitochondria oxidative stress defense, J Biol Chem 282(33), 24407-15 Salvioli, S., Storci, G., Pinti, M., Quaglino, D., Moretti, L., Merlo-Pich, M., Lenaz, G., Filosa, S., Fico, A., Bonafe, M., Monti, D., Troiano, L., Nasi, M., Cossarizza, A., and Franceschi, C (2003) Apoptosis-resistant phenotype in HL-60-derived cells HCW-2 is related to changes in expression of stress-induced proteins that impact on redox status and mitochondrial metabolism, Cell Death Differ 10(2), 163-74 Scheppach, W., and Weiler, F (2004) The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 7(5), 563-7 Schwarzer, C., Barnikol-Watanabe, S., Thinnes, F.P., Hilschmann, N (2002) Voltagedependent anion-selective channel (VDAC) interacts with the dynein light chain Tctex1 and the heat-shock protein PBP74 Int J Biochem Cell Biol 34(9), 1059-70 Sengupta, S., Muir, J.G., and Gibson, P.R (2006) Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 21(1 Pt 2), 209-18 Seo, J., and Lee, K.J (2004) Post-translational modifications and their biological functions: proteomic analysis and systematic approaches, J Biochem Mol Biol 37(1), 35-44 Seow, A., Koh, W.P., Chia, K.S., Shi, L., Lee, H.P., and Shanmugaratnam, K (2004) Trends in cancer incidence in Singapore 1968-2002, Singapore Cancer Registry Report No 6, 8-99 Serrano, D., Lazzeroni, M., and Decensi, A (2004) Chemoprevention of colorectal cancer: an update, Tech Coloproctol 8, S248-S252 Siavoshian, S., Segain, J.P., Kornprobst, M., Bonnet, C., Cherbut, C., Galmiche, J.P., and Blottière, H.M (2000) Butyrate and trichostatin A effects on the proliferation/differentiation 151 Bibliography of human intestinal epithelial cells: induction of cyclin D3 and p21 expression Gut 46(4), 507-14 Sieber, O.M., Heinimann, K., and Tomlinson, I.P (2003) Genomic instability the engine of tumorigenesis? Nat Rev Cancer 3(9), 701-8 Skulachev, V.P (2001) Mitochondrial filaments and clusters as intracellular powertransmitting cables, Trends Biochem Sci 26(1):23-9 Somech, R., Izraeli, S.J., and Simon, A (2004) Histone deacetylase inhibitors a new tool to treat cancer, Cancer Treat Rev 30(5), 461-72 Takano, S., Wadhwa, R., Mitsui, Y., and Kaul, S.C (2001) Identification and characterization of molecular interactions between glucose-regulated proteins (GRPs) mortalin/GRP75/peptide-binding protein74 (PBP74) and GRP94, Biochem J 357(Pt2), 393-8 Tan, S., Teck, K.S., Liang, R.C.M.Y., Koh, S., Lee, C.P.C., Chung, M.C.M., and Hooi, S.C (2002) Proteome analysis of butyrate-treated human colon cancer cells (HT-29), Int J Cancer 98, 523-531 Tan, H.T., Zubaidah, R.M., Tan, S., Hooi, S.C., and Chung, M.C (2006) 2-D DIGE analysis of butyrate-treated HCT-116 cells after enrichment with heparin affinity chromatography, J Proteome Res 5(5), 1098-106 Tappenden, K.A., Thomson, A.B.R., Wild, G., and McBurney, M.I (1997) Short-chain fatty acid-supplemented total parenteral nutrition enhances functional adaptation to intestinal resection in rats, Gastroenterology 112, 292-802 Taylor, S.W., Fahy, E., and Ghosh, S.S (2003) Global organellar proteomics, Trends Biotechnol 21, 82-88 Terui, T., Murakami, K., Takimoto, R., Takahashi, M., Takada, K., Murakami, T., Minami, S., Matsunaga, T., Takayama, T., Kato, J., and Niitsu, Y (2003) Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors, Cancer Res 63(24), 8948-54 Thiede, B., Siejak, F., Dimmler, C., and Rudel, T (2002) Prediction of translocation and cleavage of heterozygous ribonuclear proteins and Rho guanine nucleotide dissociation inhibitor during apoptosis by subcellular proteome analysis, Proteomics 2, 996-1006 Tong, X., Yin, L., Joshi, S., Rosenberg, D.W., and Giardina, C (2005) Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors, J Biol Chem 280(16), 15503-9 152 Bibliography Um, J.H., Kang, C.D., Hwang, B.W., Ha, M.Y., Hur, J.G., Kim, D.W., Chung, B.S., and Kim, S.H (2003) Involvement of DNA-dependent protein kinase in regulation of the mitochondrial heat shock proteins, Leuk Res 27(6), 509-16 Vandermoere, F., El Yazidi-Belkoura, I., Demont, Y., Slomianny, C., Antol, J., Lemoine, J., and Hondermarck, H (2007) Proteomics exploration reveals that actin is a signaling target of the kinase Akt, Mol Cell Proteomics 6(1), 114-24 Verma, M., Kagan, J., Sirdranksy, D., and Srivastava, S (2003) Proteomics analysis of cancer-cell mitochondria, Nat Rev Cancer 3, 789-795 Wadhwa, R., Kaul, S.C., Sugimoto, Y., and Mitsui, Y (1993) Induction of cellular senescence by transfection of cytosolic mortalin cDNA in NIH 3T3 cells, Biol Chem 268(30), 22239-42 Wadhwa, R., Kaul, S.C., and Mitsui, Y (1994) Cellular mortality to immortalization: mortalin, Cell Struct Funct 19(1), 1-10 Wadhwa, R., Pereira-Smith, O.M., Reddel, R.R., Sugimoto, Y., Mitsui, Y., and Kaul, S.C (1995) Correlation between complementation group for immortality and the cellular distribution of mortalin, Exp Cell Res 216(1), 101-6 Wadhwa, R., Takano, S., Robert, M., Yoshida, A., Nomura, H., Reddel, R.R., Mitsui, Y., and Kaul, S.C (1998) Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member J Biol Chem 273(45), 29586-91 Wadhwa, R., Sugihara, T., Yoshida, A., Nomura, H., Reddel, R.R., Simpson, R., Maruta, H., and Kaul, S.C (2000) Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function, Cancer Res 60(24), 6818-21 Wadhwa, R., Taira, K., and Kaul, S.C (2002) An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones 7(3), 30916 Wadhwa, R., Ando, H., Kawasaki, H., Taira, K., and Kaul, S.C (2003a) Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes, EMBO Rep 4(6), 595-601 Wadhwa, R., Yaguchi, T., Hasan, M.K., Taira, K., and Kaul, S.C (2003b) Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation, Biochem Biophys Res Commun 302(4), 735-42 Wadhwa, R., Takano, S., Taira, K., and Kaul, S.C (2004) Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells, J 153 Bibliography Gene Med 6, 439-444 Wadhwa, R., Takano, S., Kaur, K., Aida, S., Yaguchi, T., Kaul, Z., Hirano, T., Taira, K., Kaul, S.C (2005) Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60, Biochem J 391(Pt 2), 185-90 Wadhwa, R., Takano, S., Kaur, K., Deocaris, C.C., Pereira-Smith, O.M., Reddel, R.R., Kaul, S.C (2006) Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis, Int J Cancer 118, 2973-2980 Warburg, O (1956) On the origin of cancer cells, Science 123(3191), 309-14 Watson, A.J (2006) An overview of apoptosis and the prevention of colorectal cancer, Crit Rev Oncol Hematol 57(2), 107-21 Webster, T.J., Naylor, D.J., Hartmann, D.J., Hoj, P.B., Hoogenraad, N.J (1994) cDNA cloning and efficient mitochondrial import of pre-mtHSP70 from rat liver, DNA Cell Biol.13(12), 1213-20 Widodo, N., Deocaris, C.C., Kaur, K., Hasan, K., Yaguchi, T,, Yamasaki, K., Sugihara, T., Ishii, T., Wadhwa, R., and Kaul, S.C (2007) Stress chaperones, mortalin, and pex19p mediate 5-aza-2' deoxycytidine-induced senescence of cancer cells by DNA methylationindependent pathway, J Gerontol A Biol Sci Med Sci 62(3), 246-55 Williams, E.A., Coxhead, J.M., and Mathers, J.C (2003) Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms, Proc Nutr Soc 62, 107–115 Wilkins, MR., Pasquali, C., Appel, RD., Ou, K., Golaz, O., Sanchez, JC., Yan, JX., Gooley, AA., Hughes, G., Humphery-Smith, I., Williams, KL., and Hochstrasser DF (1996) From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis, Biotechnology 14(1), 61 – 65 Winawer, S.J (2005) Screening of colorectal cancer: progress and problems, Recent Results Cancer Res 166:231-44 Wong, C.S., Sengupta, S., Tjandra, J.J., and Gibson, P.R (2005) The influence of specific luminal factors on the colonic epithelium: high-dose butyrate and physical changes suppress early carcinogenic events in rats, Dis Colon Rectum 48(3), 549-59 Worthley, D.L., Whitehall, V.L., Spring, K.J., and Leggett, B.A (2007) Colorectal carcinogenesis: Road maps to cancer, World J Gastroenterol 13(28), 3784-91 Yaguchi, T., Aida, S., Kaul, S.C., and Wadhwa, R (2007) Involvement of mortalin in cellular senescence from the perspective of its mitochondrial import, chaperone, and oxidative 154 Bibliography stress management functions, Ann N Y Acad Sci 1100, 306-11 Yoshida, M., Kijima, M., Akita, M., and Beppu, T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, J Biol Chem 265(28), 17174-9 Zhang, D., Tai, L.K., Sethi, S.K., and Koayl, E.S.C (2006) Comparative Proteomics of Colorectal Cancer: Abnormal Expression of Proteins within the Tumor Nest and Implication of HnRNP A1 as an Oncoprotein in Tumorigenesis, Journal of Cancer Molecules 2(1), 17-24 (web link: http://www.mupnet.com/JOCM%202(1)%2017-24.htm) 155 List of Conferences and Poster Presentations LIST OF CONFERENCES AND POSTER PRESENTATIONS LF Kuah, SBE Tan, and MCM Chung Analysis of the Mitochondrial Proteome of Butyrate-Treated HCT-116 Colorectal Cancer Cells Combined Scientific Meeting 2005, CSM05 November 4-6, 2005 Raffles City Convention Centre, Raffles City, Singapore LF Kuah, S Tan, SC Hooi, and MCM Chung Analysis of the Mitochondrial Proteome of Butyrate-Treated HCT-116 Colorectal Cancer Cells Joint 3rd Asian Oceania Human Proteomics Organisation (AOHUPO) & 4th Structural Biology and Functional Genomics Conference December 4-7, 2006 University Cultural Centre, National University of Singapore, Singapore LF Kuah, S Tan, SC Hooi, and MCM Chung Mortalin is Involved in the Mitochondrial Response of HCT-116 Human Colorectal Cancer Cells to HDAC Inhibitor (Butyrate) Treatment 39th International Congress on Pathophysiology of Pregnancy November 22-24, 2007 Suntec City Convention Centre, Suntec City, Singapore 156 Appendix Appendix: Poster Appendix Appendix: Poster Appendix Appendix: Poster [...]... Subcellular distribution of mortalin and its regulation by 24-hr butyrate treatment in HCT 116 cells 92 3.16 Expression of mortalin in HCT 116 nuclear and cytosolic fractions upon 24-hr butyrate treatment 94 3.17 Subcellular distribution of mortalin and its regulation by 24-hr butyrate treatment in HT-29 cells 97 3.18 Expression of mortalin in HT-29 whole-cell and subcellular fractions upon 24-hr butyrate. .. Enrichment of mortalin isoforms and presence of additional isoforms in HCT 116 mitochondrial fraction, relative to whole cell lysate 82 3.12 Butyrate effects on the 2-DE profile of mortalin isoforms in HCT 116 whole cell lysates 84 xi 3.13 Butyrate effects on the 2-DE profile of mortalin isoforms in HCT 116 mitochondrial fractions 87 3.14 In silico prediction of phosphorylation sites in mortalin protein sequence... butyrate- treated mitochondrial fractions of HCT 116 cells 69 3.7 Butyrate regulation of well-characterised mitochondrial proteins in HCT 116 mitochondrial fraction 71 3.8 Other butyrate- regulated proteins in HCT 116 mitochondrial fraction 72 3.9 2-DE profile of mortalin isoforms in HCT 116 whole cell lysate 79 3.10 2-DE profile of mortalin isoforms in HCT 116 mitochondrial fraction 81 3.11 Enrichment of mortalin. .. route of administration of exisiting and new therapeutic agents would be tailor-made to enhance the recovery and quality of life of the individual Such ideal forms of cancer therapy rely heavily on understanding the molecular mechanisms involved in carcinogenesis and the mechanism(s) of action of effective chemotherapeutic agents 1.1.5 Early cellular events in CRC carcinogenesis The intestinal epithelium... Scansite and recent literature 90 3.5 Summary of the subcellular expression and butyrate regulation of mortalin isoforms in HCT 116 and HT-29 102 x LIST OF FIGURES Figure PAGE 1.1 Global and local rates of incidence and mortality of CRC 2 1.2 Molecular changes underlying the CRC carcinogenesis through ACS 8 1.3 Butyrate ion and its role as a SCFA in healthy colonic homeostasis 16 1.4 Regulation of gene... through the activities of HATs and HDACs 18 1.5 The HDAC family in humans 21 1.6 HDACi effects of butyrate on histone and non-histone proteins 22 1.7 Mechanisms of MOMP proposed by current literature 29 3.1 1-DE profile of whole cell lysates and mitochondrial fractions; and immunodetection of mitochondrial marker enrichment 58 3.2 DIGE comparison of the proteomes of HCT 116 crude whole cell lysate and. .. driven the search of new technologies and treatment regimens to enable earlier diagnosis and higher survival rate of CRC patients The current challenges in CRC cancer research can be summarised as follows:(i) The search for early biomarkers, which are also more sensitive and specific, for the rapid diagnosis and subsequent prognosis of the disease (ii) The discovery and optimisation of new chemotherapeutic... INTRODUCTION 1.1 COLORECTAL CANCER (CRC) 1.1.1 Epidemiology Colorectal cancer (CRC) forms in the tissues of the colon and rectum, and is currently the third most common cancer worldwide, ranking after lung and breast cancers (Kamangar et al., 2006) This malignancy alone accounts for over a million new cancer cases and over 500,000 cancer deaths annually (Figure 1.1) Its incidence concentrates in the developed... date, many hypotheses have been made for the beneficial effects of dietary fibre in preventing CRC These include the stool bulking properties of roughage, promotion of bowel movement, reduction of colonic pH, alteration of bile acid metabolism, and the increase in the production of short chain fatty acids (SCFAs) These can minimise mucosal damage by carcinogens and toxic by-products of colonic bacterial... propionate, and butyrate — are metabolized via mitochondrial β-oxidation as the primary and preferred energy source of healthy colonocytes (Heerdt and Augenlicht, 1991) They are known to decrease colonic and faecal pH, and are important for the establishment and maintenance of the colonic mucosal homeostasis in both humans and rodents (Harig et al., 1989; Tappenden et al., 1997) 13 Introduction 1.2 BUTYRATE AND ... death This supports the association of the protective effects of butyrate with its biochemical effects on the mitochondria of cancer cells viii In particular, one of the mitochondrial proteins... Enrichment of mortalin isoforms and presence of additional isoforms in HCT 116 mitochondrial fraction, relative to whole cell lysate 82 3.12 Butyrate effects on the 2-DE profile of mortalin isoforms... Scansite and recent literature 90 3.5 Summary of the subcellular expression and butyrate regulation of mortalin isoforms in HCT 116 and HT-29 102 x LIST OF FIGURES Figure PAGE 1.1 Global and local